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Viruses that establish a persistent infection, involving intracellular latency, commonly
stimulate cellular DNA synthesis and sometimes cell division early after infection. However,
most cells of metazoans have evolved “fail-safe” responses that normally monitor
unscheduled DNA synthesis and prevent cell proliferation when, for instance, cell proto-
oncogenes are “activated” by mutation, ampliﬁcation, or chromosomal rearrangements.
These cell intrinsic defense mechanisms that reduce the risk of neoplasia and cancer are
collectively called oncogenic stress responses (OSRs). Mechanisms include the activation
of tumor suppressor genes and the so-called DNA damage response that together trigger
pathways leading to cell cycle arrest (e.g., cell senescence) or complete elimination of cells
(e.g., apoptosis). It is not surprising that viruses that can induce cellular DNA synthesis and
cell division have the capacity to trigger OSR, nor is it surprising that these viruses have
evolved countermeasures for inactivating or bypassingOSR.Themain focus of this review is
how the human tumor-associated Epstein–Barr virus manipulates the host polycomb group
protein system to control – by epigenetic repression of transcription – key components of
the OSR during the transformation of normal human B cells into permanent cell lines.
Keywords: Epstein–Barr virus, PcG, epigenetic, oncogenic stress response, oncogene-induced senescence,
p16INK4a, BIM, B cell transformation
INTRODUCTION – THE BIOLOGY OF EPSTEIN–BARR
VIRUS (EBV)
Epstein–Barr virus (EBV) is a human gamma-herpesvirus
(HHV4) and as such is characterized by a tropism for lym-
phocytes and an ability to persist life-long in the infected host.
Data on persistent EBV infection in humans are consistent with
the viral genome residing in a population of long-lived, largely
non-dividing memory B cells. To establish persistence, EBV ﬁrst
infects resting (naïve) B cells – probably in tissues of the orophar-
ynx – and transiently drives these to proliferate as activated
B-blasts. The expanding B-blast population is thought to then
either migrate into, or nucleate the formation of, a germinal cen-
ter in local lymphoid tissue and therein the cells differentiate to
become centroblasts, centrocytes, and ﬁnally resting memory B
cells that enter the peripheral circulation (reviewed in Thorley-
Lawson and Gross, 2004; Roughan and Thorley-Lawson, 2009).
While the precise series of events that the EBV-positive B cells
undergo to reach the memory compartment is not yet known,
it is generally agreed that it involves regulated shut-down of
latent EBV gene expression from an initial state called latency
III, via latency II, until in quiescent memory B cells no EBV
proteins can be detected in a state called latency 0. However,
there is still some controversy as to whether or not the differ-
entiation of EBV-infected B-blasts to resting memory B cells can
occur anywhere outside the microenvironment of a germinal cen-
ter (Rowe et al., 2009; Heath et al., 2012; Thorley-Lawson et al.,
2013).
In more than 90% of the global population, following primary
infection in infancy, EBV establishes an asymptomatic, stable, life-
long, persistent infection in this long-lived pool of circulating
memory cells. Periodic activation of an infected memory B cell by
exposure to cognate antigen or aberrant T cell activity is thought
to trigger plasma cell differentiation and concomitant “lytic” viral
replication with the production of infectious virus that is released
in the oropharynx and shed in saliva (reviewed in Thorley-Lawson
and Gross, 2004; Laichalk and Thorley-Lawson, 2005; Roughan
and Thorley-Lawson, 2009).
Primary EBV infection can cause the benign self-limiting dis-
ease infectious mononucleosis (IM) in some adolescents who were
not infected in childhood. Uncontrolled proliferation of infected
B cells in the immunocompromised of any age may result in a fatal
form of IM, a chronic B lymphoproliferative disease or rarely the
development of malignant immunoblastic lymphoma (Williams
and Crawford, 2006). In normal individuals EBV-infected B-blasts
are targets for EBV-speciﬁc cytotoxic T lymphocytes (CTLs) that
recognize and destroy the EBV-infected proliferating B-blasts –
so an equilibrium is established between B-blast proliferation
on the one hand, and their immune-mediated elimination or
differentiation to resting memory B cells on the other (Bab-
cock et al., 1999; Thorley-Lawson and Gross, 2004; Hislop et al.,
2007). Individuals who are co-infected with malaria or HIV are at
increased risk of developing EBV-associated lymphomas, includ-
ing Burkitt’s lymphoma (BL). EBV is also etiologically linked
to subgroups of Hodgkin’s lymphoma (HL) and diffuse large
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B cell lymphoma (DLBCL), in addition to various non-B cell
malignancies (reviewed in Young and Rickinson, 2004).
Infection of resting naïve B cells ex vivo with EBV can also
induce the proliferation of the B-blast-like cells that in vivo would
differentiate to become memory cells. In vitro these B cells do
not differentiate, but are transformed to continuously prolif-
erating permanent lymphoblastoid cell lines (LCLs) that retain
the activated B cell phenotype and carry the viral genome as
extra-chromosomal episomes. Only the nine latency III-associated
proteins six nuclear (EBNAs 1, 2, 3A, 3B, 3C, and LP) and three
membrane-associated (LMP1, LMP2A, and 2B) together with sev-
eral RNA species are expressed from the viral genome (reviewed
in Bornkamm and Hammerschmidt, 2001; Young and Rickin-
son, 2004; Forte and Luftig, 2011). These latency-associated gene
products are responsible for activating the quiescent primary cells
into the cell cycle, inducing and sustaining their proliferation and
maintaining the extrachromosomal episome in these blast-like
cells. There is general agreement – that at least in the initial stages
after infection – LCL outgrowth recapitulates the early events of
establishing latency prior to differentiation and long-term per-
sistence in vivo. EBV may therefore be considered one of the
few viruses that initiate and sustain the proliferation of infected
cells as a necessary step in their life cycle, in the natural host.
Some of the molecular details of how EBV does this in the face
of intrinsic barriers to aberrant proliferation are the focus of this
review. Speciﬁc attentionwill be paid to thepolycombgroup (PcG)
protein-mediated epigenetic repression of the cyclin-dependent
kinase inhibitor p16INK4a and the pro-apoptotic BH3-only inducer
of apoptosis BIM.
ONCOGENIC STRESS RESPONSES (OSRs) AND
ONCOGENE-INDUCED SENESCENCE (OIS)
The seminal discovery in 1992 that the Myc proto-oncoprotein
can trigger rapid apoptosis as well as cell growth and proliferation,
led to the compelling hypothesis that apoptotic pathways must
be disabled for oncogenes to promote neoplastic transformation
of cells and the development of cancer (Askew et al., 1991; Evan
et al., 1992). About 5 years later an equally inﬂuential discovery
was that oncogenic mutant Ras protein – in addition to activating
proliferative signaling pathways – also provokes in normal ﬁbrob-
lasts a cell cycle arrest resembling premature cell senescence. This
was associated with the accumulation of tumor suppressors (ts)
p53 and p16INK4a (Serrano et al., 1997), and further endorsed the
hypothesis that normalmammalian cells possess intrinsic defenses
against oncogenic transformation. These observations inspired
the concepts of “OSR,” “intrinsic tumor suppression,” and “OIS”
and produced many detailed descriptions of mechanisms involv-
ing the p53 and retinoblastoma (Rb) tumor suppressor pathways
that prevent deregulated oncogenes causing cancer (Figure 1;
reviewed in Sherr, 1998, 2012; Lowe et al., 2004; Braig and Schmitt,
2006).
RELATIONSHIP BETWEEN OSR/OIS AND DNA DAMAGE
RESPONSES (DDRs)
Since cell proto-oncogenes generally control signaling pathways
and/or gene networks that link proliferative signals to the cell cycle
FIGURE 1 | Activation of cell proto-oncogenes can lead to oncogenic
stress responses (OSR). Oncogene “activation” by mutation or
constitutive expression at supra-physiological levels can induce aberrant
cell division that may become manifest as rapid cell proliferation
(hyperproliferation). However higher vertebrates have evolved cell intrinsic
“fail-safe” responses to recognize such cells and so block their proliferation
or eliminate them completely. These can include the induction of tumor
suppressors (ts) such as p16INK4a that halt the cell cycle and can cause
cells to enter a prolonged state of arrest called senescence, or
pro-apoptotic proteins such as BIM that can induce programmed cell death
(apoptosis). Responses may involve direct activation of the ts genes by
oncoproteins or they can result from secondary signaling pathways (DDR)
linked to the detection of damaged DNA produced during periods of
aberrant DNA replication and cell division.
machinery, when they are deregulated this can result in unsched-
uled entry into S phase and aberrant DNA synthesis (sometimes
referred to as “replicative stress”). As a consequence, oncogene
activation can produce the stalling of DNA replication forks that
results in damaged DNA – particularly double strand breaks. Such
lesions can also be caused by the action of multiple physical and
chemical agents and they can trigger, primarily via the ATM/ATR-
kinase signaling pathway, the stabilization and activation of p53
and also the induction of 16INK4a. Depending on the physio-
logical and cellular context this leads to DNA repair, cell death,
or senescence. This complex response is known as the DDR. It
has been proposed that the induction of apoptosis or cell cycle
arrest/senescence by oncogenic stress is a general downstream
manifestation of the DDR acting as a barrier to cell transforma-
tion in vitro and tumor progression in vivo (Di Micco et al., 2006;
Bartek et al., 2007; Halazonetis et al., 2008). However, it remains
unclear whether all oncogene-mediated stress responses act via
the DDR, or whether alternative signaling pathways directly regu-
late downstream effectors (see for example induction of p16INK4a
in response to oncogenic RAS/RAF signaling (Agger et al., 2009;
Barradas et al., 2009) and the relationship between MYC and
BIM in B cell lymphomas described below). The links between
DDR, OSR, and OIS have been extensively reviewed (Braig and
Schmitt, 2006; Gil and Peters, 2006; Kim and Sharpless, 2006;
Wade and Wahl, 2006; Bartek et al., 2007; Halazonetis et al.,
2008).
A common feature of herpesviruses is their capacity to acti-
vate DDRs in infected cells (Shirata et al., 2005; Gaspar and
Shenk, 2006; Koopal et al., 2007; Tarakanova et al., 2007; Nikitin
et al., 2010). Although in some cases this is associated with lytic
or productive infection, when the virus has a requirement for
rapid replication of its genome prior to virion assembly, at
least two gamma-herpesviruses (Kaposi’s Sarcoma associated her-
pes virus (KSHV, aka HHV8) and EBV) trigger DDRs during
the establishment of a latent infection. This is largely because
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latency-associated viral proteins drive cells into the cell cycle
and can induce hyperproliferation, replication errors, and asso-
ciated DNA damage (Koopal et al., 2007; Nikitin et al., 2010).
Moreover, it has been suggested that EBV infection of B cells
in vitro may also induce reactive oxygen species (ROS) that
can damage DNA (reviewed in Allday, 2009; Gruhne et al.,
2009). EBV and KSHV appear to have evolved mechanisms
for the attenuation of the DDR to ensure latent infection is
maintained. Virus-associated responses involving the DDR have
recently been comprehensively reviewed elsewhere (Leidal et al.,
2012; Nikitin and Luftig, 2012) and for EBV will be reconsidered
below.
THE INK4b-ARF-INK4a LOCUS, p16INK4a, OSR/OIS, AGING,
AND CANCER
Within the INK4b-ARF-INK4a locus at human chromosome9p21,
CDKN2A encodes two potent tumor suppressors, p16INK4a, and
p14ARF (p19ARF in mice); these proteins are critical negative reg-
ulators of cell proliferation. Although exons 2 and 3 are shared
by INK4a and ARF, the proteins result from differential splicing
and are encoded in alternative reading frames (reviewed in Gil
and Peters, 2006; Kim and Sharpless, 2006; Sherr, 2012). Adja-
cent to CDKN2A is a second related gene CDKN2B that encodes
a protein closely related to p16INK4a called p15INK4b (Figure 2).
The cyclin-dependent kinase (CDK) inhibitor p16INK4a acts on the
cyclin D-dependent kinases (CDK4 and CDK6) abrogating their
binding to D-type cyclins and so inhibiting CDK4/6-mediated
phosphorylation of the Rb protein. By bindingCDKs and blocking
Rb hyperphosphorylation, increased p16INK4a expression causes a
G1 cell cycle arrest and senescence (Gil and Peters, 2006; Kim
and Sharpless, 2006; Sherr, 2012). Although the CDK inhibitor
p15INK4b has about 85% amino acid similarity to p16INK4a and
biochemically behaves in much the same way, in most mammalian
cells – for unknown reasons – it has distinct functions. In contrast
to the CDK inhibitors, the p14 and p19 ARF proteins regulate the
stability of p53 by inactivating MDM2 – a p53-speciﬁc ubiquitin
ligase that facilitates p53 degradation. The concomitant stabiliza-
tion and activation of p53 leads to G1 and G2 cell cycle arrest by
inducing the CDK regulator p21WAF1 or apoptosis by inducing
pro-apoptotic factors such as NOXA and PUMA (Vousden and
Prives, 2009; Sherr, 2012).
The products of CDKN2A can therefore be key mediators of
OSRandpotent barriers to the“immortalization”of cells in culture
and the development of cancers in vivo. Both p16INK4a and ARF
are also progressively up-regulated with tissue aging, when they
probably contribute to the aging process by reducing reservoirs
of stem cells capable of self-renewal (Kim and Sharpless, 2006;
Collado et al., 2007). There is general agreement that p19ARF plays
the more important role in all these processes in mice, whereas
in human cells p16INK4a is the dominant player. It is therefore
not surprising that in a wide variety of human cancers INK4a is
inactivated by gene deletion, mutation, or promoter DNA methy-
lation (Gil and Peters, 2006; Kim and Sharpless, 2006; Popov and
Gil, 2010). The whole INK4b-ARF-INK4a locus appears to be
coordinately regulated epigenetically by polycomb protein com-
plexes generating repressive histone modiﬁcations (Gil and Peters,
2006; Popov and Gil, 2010). Although induction of p16INK4A in
FIGURE 2 | Epitope-tagged EBNA3C associates with the promoter
for BIM and genes in the INK4b-ARF-INK4a locus. Schematic
representations of (A) approximately 9kb of the BCL2L11 (BIM) promoter
and (B) approximately 40 kb including the INK4b-ARF-INK4a locus. Vertical
arrows indicate the positions where EBNA3C has been detected by
chromatin immunoprecipitation (ChIP) analyses using lymphoblastoid cell
lines (LCL) established using EBV expressing an epitope-tagged EBNA3C.
These same regions of chromatin are marked by the polycomb
(PRC2)-mediated modiﬁcation H3K27me3 when EBNA3A and EBNA3C
are present (adapted from Paschos et al., 2012; Skalska et al., 2013). The
BCL2L11 gene transcriptional start site (TSS) and the protein products of
INK4b-ARF-INK4a are indicated. A–G in (A) mark the positions of RT-PCR
primer sets used in (Paschos et al., 2012).
ﬁbroblasts and epithelial cells is generally associated with cell cycle
arrest and senescence, in B cells – which exhibit no obvious char-
acteristics of senescence – there may be some crosstalk between
p16INK4a and the apoptotic machinery, since in lymphocytes the
default pathway triggered by p16INK4a can be death rather than
prolonged cell cycle arrest (Lagresle et al., 2002; Bianchi et al.,
2006).
BIM, B CELLS, AND MYC
BIM (Bcl2-interacting mediator) is a pro-apoptotic member of
the BH3-only family of BCL2-like proteins and is encoded by the
BCL2L11 gene at human chromosome 2q13. BIM acts as a potent,
direct initiator of apoptosis because it binds with high afﬁnity to
BCL2 and all the other pro-survival family members to inactivate
them. BIM also binds and activates pro-apoptotic BAX to initiate
cytochrome-c release from mitochondria (Strasser, 2005; Gavathi-
otis et al., 2008). BIM is particularly important in the immune
system, acting as a major regulator of life-and-death decisions
during lymphocyte development including the negative selection
of auto-reactive B cells and programmed death of low-afﬁnity
antibody-expressing germinal center-derived B cells (Enders et al.,
2003; Strasser, 2005; Fischer et al., 2007). Bim-null mice accumu-
late excess lymphoid and myeloid cells and loss of Bim accelerates
B cell lymphomagenesis induced by an Eμ-Myc transgene. Even
loss of a single allele accelerates lymphomagenesis signiﬁcantly,
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indicating Bim is a haploinsufﬁcient tumor suppressor and that
the level of Bim protein is rate-limiting in murine B cell survival
(Egle et al., 2004).
Extending this Eμ-Myc-lymphoma model to human B cell
lymphomagenesis, the relationship between MYC and BIM in
EBV-negative BL was investigated (Dang et al., 2005; Hemann
et al., 2005). This study brought into sharp focus the activation
of BCL2L11/BIM by MYC, and led to the proposal that MYC-
induced apoptosis can be overridden by inactivation of any one
of several MYC effectors – including p53, p14ARF, or BIM –
causing apoptosis-ﬁring to drop below a critical threshold to
allow cell proliferation. It also established that BCL2L11/BIM
is a p14ARF/p53-independent target of MYC and that its acti-
vation does not require MYC-induced hyperproliferation (Dang
et al., 2005; Hemann et al., 2005). Thus BIM is a uniquely impor-
tant tumor suppressor in cells of the hematopoietic lineage and
operationally its activation by MYC is a component of the OSR
in B cells. Since MYC is induced and becomes constitutively
expressed early after EBV infection of primary human B cells,
modulation of BIM expression by EBV is likely to be a contrib-
utory factor in B cell transformation and the development of
any EBV-associated B cell lymphomas (discussed in more detail
below).
POLYCOMB GROUP PROTEINS AND EPIGENETIC
REPRESSION
Epigenetic gene regulation is heritable and results from changes in
a chromosome without alterations to DNA sequence (Berger et al.,
2009). Such changes can be mediated by chemical modiﬁcations
to chromatin on either DNA or DNA-associated histones and may
involve non-coding RNAs. PcG proteins were ﬁrst identiﬁed in
Drosophila and are best known as repressors of the homeotic (Hox)
transcription factor genes during embryonic development. They
are very highly conserved from ﬂies to humans and homologues
regulating developmental transitions are found in plants. PcGpro-
teins form multi-protein complexes called polycomb repressive
complexes (PRCs) that bind and epigenetically regulate hundreds
of genes, predominantly associated with cell-fate decisions and
development (reviewed in Bracken and Helin, 2009; Margueron
and Reinberg, 2011; Bemer and Grossniklaus, 2012; Simon and
Kingston, 2013). They can repress transcription by introducing
post-translational covalent modiﬁcations on histones in chro-
matin located in the regulatory regions of target genes. This
repression/silencing is stable and heritable so can be described
as epigenetic (Berger et al., 2009).
PRC2 is a multi-component complex that mediates tri-
methylation at lysine 27 of histone H3 (H3K27me3). In humans
the core complex is comprised of three polycomb proteins: sup-
pressor of zeste (SUZ)12, embryonic ectoderm development
(EED), and enhancer of zeste (EZH)2. EZH2 contains the cat-
alytic SET domain responsible for lysinemethyltransferase activity
(Bracken and Helin, 2009; Margueron and Reinberg, 2011; Simon
and Kingston, 2013). Other components of PRC2 are histone
chaperone RbAp46/48 and recently an ancillary factor, JARID2,
has been identiﬁed as being essential for recruitment of PRC2
to some polycomb-target genes (Murzina et al., 2008; Landeira
et al., 2010; Margueron and Reinberg, 2011; Simon and Kingston,
2013). It remains unclear how in most cases the polycomb pro-
teins are recruited to speciﬁc promoters in mammalian cells,
although sequence context is probably important and a prefer-
ence for regions rich in CpG dinucleotides (CpG-islands) has
been reported (Ku et al., 2008). However, for most target genes,
it remains to be determined whether speciﬁcity comes from
sequence-speciﬁc transcription factors, PRC2-interacting non-
coding RNA species, or yet to be identiﬁed mechanisms (Bracken
and Helin, 2009; Khalil et al., 2009; Gupta et al., 2010; Kanhere
et al., 2010; Simon and Kingston, 2013).
H3K27me3 on chromatin attracts the binding of a second com-
plex, PRC1 that mediates the repressive ubiquitinylation at lysine
119 of histone H2A (H2AK119Ub). PRC1 core proteins include
chromobox (CBX) proteins, whose chromodomains are thought
to recruit the complex to the H3K27me3 mark, and RING ﬁnger
proteins, such as RING1B, MEL18, and BMI1 that are responsi-
ble for the E3 ubiquitin ligase activity that produces H2AK119Ub.
PRC1 mediates chromatin compaction and the local formation
of heterochromatin (Grau et al., 2011) and together with PRC2,
increases the chances of the more stable CpG DNA methyla-
tion mark being deposited (reviewed in Cedar and Bergman,
2009). Although recent evidence suggests H3K27me3 is stable
and heritable (Simon and Kingston, 2013) this histone modiﬁ-
cation can be rapidly removed by demethylase enzymes such as
JMJD3 (aka KDM6B; Agger et al., 2009; Barradas et al., 2009).
Moreover, if a promoter carries H3K27me3 and simultaneously
has the activation-associated modiﬁcation H3K4me3 at the same
locus, it is repressed but is described as “bivalent” and thought to
be poised for rapid reactivation by removal of H3K27me3; genes
with such bivalent domains are common in stem cells (Bern-
stein et al., 2006; Voigt et al., 2013). Cancer cells and stem cells
often share gene expression patterns and multiple reports suggest
that polycomb complexes contribute to the aberrant CpG DNA
methylation proﬁles that are critical in the genesis and progres-
sion of many diverse cancers (Cedar and Bergman, 2009). The
mechanism for this is suggested by the capacity of various poly-
comb proteins to physically interact with DNA methyl transferases
(DNMTs) and recruit them to chromatin. It has been estimated
that PcG-target genes are up to 12 times more likely to be aber-
rantly methylated in cancer than non-targets (Widschwendter
et al., 2007).
EPIGENETIC REGULATION OF BIM AND p16INK4a EXPRESSION
BY EBV
EBNA3A AND EBNA3C COOPERATE AS ONCOGENIC REPRESSORS OF
TRANSCRIPTION
The EBV EBNA3 proteins (EBNA3A, EBNA3B, and EBNA3C)
are large (>900 aa) latency-associated nuclear proteins that show
no signiﬁcant similarity to known cell or viral factors. Although
none of them appears to bind DNA directly, they all bind the
cellular DNA-binding factor CBF-1 (aka RBP-JK; reviewed in
Bornkamm and Hammerschmidt, 2001; Young and Rickinson,
2004). All three EBNA3s can also interact with cellular factors
associated with the covalent modiﬁcation of histones, the repres-
sion of transcription, and gene silencing; for example, EBNA3A
and EBNA3C associate with histone deacetylases (HDACs)
and the conserved co-repressor CtBP (Radkov et al., 1999;
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BornkammandHammerschmidt, 2001; Touitou et al., 2001;Hick-
abottom et al., 2002; Young and Rickinson, 2004). EBNA3A,
EBNA3B, and EBNA3C are all robust repressors of transcription
when targeted directly toDNA in transient assays (Bain et al., 1996;
Cludts and Farrell, 1998 and our unpublished data), and EBNA3A
and EBNA3C – but not EBNA3B – are necessary to establish LCLs
from puriﬁed B cells (Tomkinson and Kieff, 1992; Tomkinson
et al., 1993). EBNA3A and EBNA3C also cooperate with onco-
genic Ha-Ras in the transformation/immortalization of primary
rodent ﬁbroblasts and require the interaction with CtBP to do this
(Parker et al., 1996; Touitou et al., 2001; Hickabottom et al., 2002).
All the data are therefore consistent with EBNA3A and EBNA3C
acting as oncoproteins in the transformation of B cells and in EBV-
associated lymphomagenesis. However EBNA3B is unnecessary in
these processes, and can even act as a tumor suppressor (White
et al., 2012).
Recentmicroarray gene-expression analyses using LCLs or lym-
phoma cells infected with recombinant B95.8 strain EBVs that
express deﬁned EBNA3mutants, suggest that together the EBNA3s
can regulate >1000 host genes in B cells – often repressing tran-
scription. The regulation of many of these genes seems to require
the functional interaction of at least two EBNA3s and in several
cases that have been subjected to further analysis, gene repres-
sion appears to utilize the host PcG system to inhibit transcription
via the H3K27me3 chromatin modiﬁcation (Hertle et al., 2009;
Skalska et al., 2010; White et al., 2010, 2012; Maruo et al., 2011;
Zhao et al., 2011; McClellan et al., 2012; Paschos et al., 2012). Two
genes repressed by the combined action of EBNA3C, EBNA3A,
and PcG proteins – and of particular interest in the context of
OSR – encode BIM and p16INK4a.
REPRESSION OF BIM TRANSCRIPTION
The ﬁrst indication that EBNA3A and EBNA3C can cooperate
to repress speciﬁc host cell genes came using a panel of EBNA3-
knockout recombinant B95.8-derivedEBVs to infect EBV-negative
BL cells. This revealed that expression of both EBNA3A and
EBNA3C are necessary to repress transcription of BCL2L11/BIM
(Anderton et al., 2008). Subsequently it was found that DNA in a
large CpG island located at the 5′ end of BCL2L11/BIM becomes
methylated on CpG dinucleotides in EBV-positive BLs (Paschos
et al., 2009). However a reduction in BIM expression occurred
soon after EBV infection of B cells in culture and did not ini-
tially involve detectable CpG methylation, but correlated with the
deposition of the polycomb signature H3K27me3 on chromatin
proximal to the transcription start site (TSS; Paschos et al., 2009,
2012). Detailed chromatin immunoprecipitation (ChIP) analyses
of the chromatin around the BCL2L11/BIM promoter revealed
that latent EBV triggers the recruitment of polycomb repressive
complex 2 (PRC2) core subunits and the trimethylation of his-
tone H3 lysine 27 (H3K27me3) at this locus. It appears that
in uninfected BL cells, RbAp48, and JARID2 already associate
with the chromatin proximal to the TSS and that EBV infection
is necessary to recruit SUZ12 and EZH2 to establish functional
PRC2. Assembly of PRC2 at the locus was absolutely dependent
on both EBNA3A and EBNA3C being expressed, and using a
recombinant EBV expressing an epitope-tagged EBNA3C, it was
shown by ChIP that EBNA3C associates with chromatin near
the TSS – it is therefore likely to physically interact with PRC2
(Paschos et al., 2012; Figure 2 and model in Figure 3). Since
the activation mark H3K4me3 is largely unaltered at this locus
irrespective of H3K27me3- or EBNA3-status the establishment
of a “bivalent” chromatin domain is suggested. Consistent with
the “poised” nature of these domains, RNA polymerase II (RNA
Pol II) occupancy at the BCL2L11/BIM TSS was not altered by
EBV. However, further analysis of phospho-serine 5 on RNA Pol
II indicated that when EBNA3A and EBNA3C are both expressed
they inhibit this phosphorylation step and block the initiation of
the BIM transcripts. It was not determined whether this involves
the direct action of an EBV protein on the kinase CDK7 or is
a consequence of the recruitment of PRC2 and/or PRC1 to this
particular locus. B cell lines carrying EBV encoding a condi-
tional EBNA3C-modiﬁed estrogen receptor-fusion revealed that
this epigenetic repression of BIM was reversible, but took more
FIGURE 3 |Working hypothesis for the role(s) of EBNA3C and EBNA3A
in the PRC2-mediated repression of the BIM promoter.The available
data indicate that EBNA3C (and EBNA3A) are recruited to regions proximal
to the BCL2L11/BIM transcriptional start site (TSS) in EBV-infected B cells
(Paschos et al., 2012; our unpublished data and Figure 2). Irrespective of
whether EBNA3C or EBNA3A are expressed in these cells, the
PRC2-associated factors RbpA46/48 and JARID2 are present at the locus.
Similarly the activation mark H3K4me3 and RNA polymerase II (RNA Pol II)
occupy theTSS irrespective of which EBNA3s are expressed. Only when
both EBNA3C and EBNA3A are present are core components of the PRC2
complex found at this site and the repressive chromatin mark H3K27me3 is
detected across theTSS; concomitantly the level of transcription and BIM
expression are reduced. The simultaneous presence of both H3K4me3 and
H3K27me3 at the locus deﬁne it as a “bivalent” or “poised” domain and is
consistent with RNA Pol II always being detected. However only in the
absence of either EBNA3C or EBNA3A is RNA Pol II phosphorylated on
serine residue 5 (RNA Pol II Ser 5), suggesting that in addition to playing a
key role in the recruitment of PRC2 core complex, the presence of
EBNA3C and EBNA3A might interfere with serine 5 phosphorylation of
RNA Pol II and therefore block the initiation of transcription. Since EBNA3A
and EBNA3C can be co-immunoprecipitated from infected B cells and both
are necessary for repression of BIM (and p16INK4a) expression, in this
model we assume they are co-localized at these loci. The identity of the
factor(s) responsible for targeting EBNA3C and/or EBNA3A to this particular
stretch of chromatin is still unknown, as is the mechanism of interaction
with PRC2.
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than 30 days from when EBNA3C was inactivated, emphasizing
the stability of these chromatin modiﬁcations through rounds
of cell division. Lentivirus delivery of shRNAs against PRC2 and
PRC1 subunits disrupted EBV repression of BCL2L11/BIM, thus
conﬁrming the requirement for PcG complexes (Paschos et al.,
2012).
REPRESSION OF TRANSCRIPTION FROM THE CDKN2A LOCUS
Direct evidence that EBNA3C modulates the cell cycle during
EBV-mediated transformation of B cells came from Maruo et al.
(2006). Using a recombinant Akata strain EBV made condi-
tional for EBNA3C function by fusing EBNA3C with a mod-
iﬁed estrogen receptor, they revealed that EBNA3C represses
expression of the CDK inhibitor p16INK4A in LCLs. Remov-
ing the inducer of EBNA3C activity (4-hydroxytamoxifen, 4HT)
from the culture medium resulted in an accumulation of both
p16INK4A mRNA and protein, de-phosphorylation of Rb, and
concomitant cell cycle arrest (Maruo et al., 2006). Using a sim-
ilar recombinant virus expressing an EBNA3A-fusion, the same
authors showed that inactivation of EBNA3A also resulted in
reduced proliferation, although the mechanism was not deter-
mined (Maruo et al., 2003). Since EBNA3A and EBNA3C are
necessary for the H3K27me3-mediated chromatin manipula-
tion and epigenetic repression of BCL2L11/BIM, and since the
CDKN2A locus that encodes p16INK4a had been identiﬁed as
a target of polycomb-mediated repression in proliferating cells,
it was not surprising to discover that the combined action of
EBNA3C and EBNA3A repressed CDKN2A in cycling B cells
by facilitating the deposition of H3K27me3 across the locus –
primarily around the p16INK4a TSS (Skalska et al., 2010). Fur-
thermore, establishing LCLs with recombinant viruses encoding
CtBP-binding mutants of EBNA3C and EBNA3A revealed that
their interaction with this highly conserved cellular co-repressor
was necessary for the efﬁcient deposition of H3K27me3 and
repression of p16INK4a expression. ChIP analysis for the epitope-
tagged EBNA3C expressed in an LCL revealed EBNA3C at the
TSS of p16INK4A and ARF, and also the CDKN2B gene encoding
p15INK4b (Figure 2; Skalska et al., 2013). Although it was initially
unclear whether the EBNA3C-associated H3K27me3 deposition
at CDKN2A was a cause or a consequence of cells exiting from
the cell cycle, regulation of the locus by EBNA3C in an Rb-
null LCL (Skalska et al., 2010) and in several p16INK4a-null LCLs
(Skalska et al., 2013 and see below) unequivocally established that
EBNA3C regulation of the locus is independent of the degree of
cell proliferation. As with BLC2L11/BIM, B cell lines carrying EBV
encoding the conditional EBNA3C-modiﬁed estrogen receptor-
fusion revealed that this epigenetic repression of CDKN2A was
reversible by adding or removing 4HT from the medium. Taken
together all these data suggest that EBNA3C (cooperating with
EBNA3A) coordinately regulates the whole INK4b-ARF-INK4a
locus by directing the recruitment of PRC2 to the three tran-
scriptional start sites. Consistent with this we have recently found
that the level of p15INK4b mRNA is coordinately regulated with
that of p16INK4a in EBNA3C-conditional LCLs (our unpublished
data).
The speciﬁc role of p16INK4a as a target forEBNA3Candamajor
barrier to B cell transformation was further explored making use
of an “experiment of nature” in the form of “Leiden” B cells car-
rying a homozygous genomic deletion that speciﬁcally ablates
production of functional p16INK4a (Brookes et al., 2002; Hayes
et al., 2004). These cells were infected with recombinant B95.8-
derived EBVs that express either the conditional EBNA3C or no
EBNA3C (Skalska et al., 2013). A comparison of p16-null LCLs
with LCLs established from normal B cells showed unequivocally
that, if p16INK4a is not functional, then EBNA3C is unnecessary
to sustain cell proliferation. Consistent with this – and provid-
ing formal proof that p16INK4a is the main target of EBNA3C –
it was possible to transform p16-null B cells into stable LCLs
with EBV, but without any functional EBNA3C ever having been
expressed.
INHIBITING OSR/OIS IS NECESSARY FOR LCL OUTGROWTH
A reasonable but speculative explanation for why EBV has evolved
a mechanism for suppressing p16INK4a (and BIM) expression
became apparent from examining the outcome of attempted
transformations of normal B cells with EBNA3C-deﬁcient EBV
(Figure 4; Skalska et al., 2013). These experiments revealed that
infection with a “wild type”EBV modestly induced p16INK4a tran-
scription in the ﬁrst few days after infection – when EBNA2
transactivates inducers of cell cycle progression (e.g., MYC and
cyclin D2) and a period of hyperproliferation has been described
(Sinclair et al., 1994; Spender et al., 1999; Nikitin et al., 2010).
It is likely that unscheduled entry into S-phase, is interpreted
by the cell as oncogenic stress and activation of p16INK4a tran-
scription is a consequence. When the infecting virus expressed
functional EBNA3C (and EBNA3A) there was a halt to the increase
of p16INK4a expression from about day 7 onwards. However, if
EBNA3C was not expressed or was non-functional (i.e., no 4HT in
the medium), transcription from INK4a continued unrestrained
and the level of mRNA progressively increased over the next
2–3 weeks, until most of the cells stopped proliferating. Early
after infection BIM expression is down-regulated, and very soon
(<5 days) reaches a steady state, but if EBNA3C is deleted or
functionally inactivated in the infecting EBV – beginning about
4 days post infection – the level of mRNA corresponding to BIM
also increases, in parallel with that of p16INK4a. This increase
continues for the next week or two until cells arrest or die
(Skalska et al., 2013). Largely similar results were obtained with
EBNA3A-negative virus (our unpublished data).
The EBNA3C/3A-mediated epigenetic inhibition of INK4a
and BCL2L11/BIM transcription is therefore critical for EBV to
bypass an intrinsic host cell defense against oncogenic trans-
formation probably triggered by EBNA2 acting through MYC
(summarized in Figure 4; see also Nikitin et al., 2010). Thus
expression of both EBNA3C and EBNA3A ensures expansion
of the infected B cell population and LCL outgrowth in vitro
and in vivo the initiation of latency. Strictly speaking, in this
context, EBNA3C and EBNA3A do not actually repress INK4a
and BCL2L11/BIM transcription, but rather prevent their acti-
vation. This most likely involves the recruitment of PcG protein
complexes to the loci, leading to H3K27me3 modiﬁcations on
chromatin around the TSSs, as is seen in established LCLs; how-
ever this has not yet been formally demonstrated in newly infected
cells.
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FIGURE 4 | Events following infection of primary resting B cells by
EBV that initiate transformation into continuously proliferating LCLs.
(A) During the ﬁrst 24–48 h post-infection (pi) with a B95.8-derived EBV,
cell genes associated with growth and cell cycle are transactivated and
their products (e.g., MYC, cyclin D2, cyclin E) drive cells from G0 to G1, to
become enlarged, activated and start proliferating. The whole process is
driven by the EBV transactivator protein EBNA2, probably assisted by the
co-factor EBNA-LP (Sinclair et al., 1994; Spender et al., 1999; Nikitin et al.,
2010). During the next 3–4 days cells undergo rounds of rapid cell division
(hyperproliferation) and in some cells this results in damage to DNA that
can activate the DNA damage response (DDR) and initiate a signaling
cascade involving the kinases ATM and CHK2 (Nikitin et al., 2010). If the
full complement of nine EBV latency-associated proteins is expressed, the
DDR becomes attenuated (in part by EBNA3C) and cells continue to
proliferate to produce polyclonal LCLs that have a population doubling time
of about 24 h. Early after infection BIM expression is down-regulated, and
although the level of p16INK4a expression increases slightly, this soon
reaches a steady state. In both cases we assume that EBNA3A and
EBNA3C cooperate by harnessing the polycomb group (PcG) protein
system to epigenetically repress (or restrain the transcription of) these ts
genes via H3K27me3 (Anderton et al., 2008; Paschos et al., 2012; Skalska
et al., 2013). (B) If EBNA3C or EBNA3A are deleted (EBNA3C and
EBNA3A) or functionally inactivated in the infecting EBV, beginning about
4–7 days pi, the levels of mRNAs corresponding to p16INK4a and BIM
progressively increase and continue to do so for the next week or two
until ﬁnally most of the cells arrest and/or die (Skalska et al., 2013 and our
unpublished data). The PcG-mediated repression of these two ts genes –
in particular p16INK4a (see text) – is part of a critical countermeasure
evolved by EBV to bypass an intrinsic host defense against oncogenic
transformation. If primary B cells are p16INK4a-null, functional EBNA3C is
dispensable for the outgrowth of LCLs. This is consistent with p16INK4a
being the dominant barrier to outgrowth and subsequent proliferation of
LCLs, and the principal requirement of EBNA3C appears to be to
restraining transcription of p16INK4a (see text for details and Skalska et al.,
2013). The precise relationships between DDR, p16INK4a and
EBNA3C/EBNA3A have yet to be deﬁned.
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CONCLUDING REMARKS
Through the combined action of EBNA3C and EBNA3A and
their interaction with the cellular PcG protein system, EBV has
evolved a very effective countermeasure to OSR/OIS that appears
to be critical in its normal life cycle to establish a latent infec-
tion and therefore initiate long-term persistence in B cells. In
vitro this mechanism neatly overcomes a major early obsta-
cle to cellular “immortalization,” making EBV one of the most
potent transforming/immortalizing biological agents to have been
identiﬁed. By utilizing an epigenetic mode of gene regulation
to tackle the problem of OSR/OIS, key target ts genes includ-
ing INK4a and BCL2L11/BIM are repressed not only in the
infected cells, but also in their progeny; furthermore the genes
become particularly predisposed to complete silencing by DNA
modiﬁcation. It is self-evident – since EBV stably ablates at
least two major barriers to oncogenic transformation – that this
will substantially increase the likelihood of EBV-infected B cells
undergoing additional genetic and/or epigenetic changes lead-
ing to cancer (discussed further in Thorley-Lawson and Allday,
2008; Allday, 2009; Skalska et al., 2010; Paschos et al., 2012).
This manipulation of the PcG system to speciﬁcally regulate
key tumor suppressor genes in B cells makes EBV – to our
knowledge – unique among tumor viruses. Now the challenges
are to provide complete biochemical descriptions of how the
EBNA3 proteins interact with PcG complexes and – employing
genome-wide screens such as ChIP-seq – determine the extent
of polycomb-mediated epigenetic reprogramming of B cells by
EBV.
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